Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of “Moderate Buy” from Analysts

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) has been given an average rating of “Moderate Buy” by the six ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $11.6667.

A number of analysts have commented on ACRV shares. Weiss Ratings raised shares of Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, April 27th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Acrivon Therapeutics in a report on Monday, March 2nd. Finally, Wall Street Zen lowered shares of Acrivon Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, March 1st.

Hedge Funds Weigh In On Acrivon Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ACRV. Invesco Ltd. acquired a new position in shares of Acrivon Therapeutics in the 1st quarter valued at $72,000. XTX Topco Ltd acquired a new position in shares of Acrivon Therapeutics in the 2nd quarter valued at $126,000. Jane Street Group LLC acquired a new position in shares of Acrivon Therapeutics in the 2nd quarter valued at $371,000. UBS Group AG grew its holdings in shares of Acrivon Therapeutics by 150,057.8% in the 3rd quarter. UBS Group AG now owns 683,218 shares of the company’s stock valued at $1,237,000 after buying an additional 682,763 shares during the period. Finally, Two Sigma Investments LP grew its holdings in shares of Acrivon Therapeutics by 76.2% in the 3rd quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock valued at $578,000 after buying an additional 138,033 shares during the period. Institutional investors and hedge funds own 71.62% of the company’s stock.

Acrivon Therapeutics Stock Performance

ACRV opened at $1.98 on Friday. The company has a fifty day moving average price of $1.67 and a two-hundred day moving average price of $1.94. Acrivon Therapeutics has a 52 week low of $1.05 and a 52 week high of $3.56. The firm has a market capitalization of $84.75 million, a PE ratio of -0.98 and a beta of 2.01.

Acrivon Therapeutics (NASDAQ:ACRV) last released its earnings results on Thursday, March 19th. The company reported ($0.49) EPS for the quarter, hitting analysts’ consensus estimates of ($0.49). Equities analysts forecast that Acrivon Therapeutics will post -2 EPS for the current year.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.